Mobile

A Single-Arm, Phase 2 Trial of Pemetrexed, Cisplatin, and Bevacizumab as Induction, Followed by Pemetrexed and Bevacizumab as Maintenance, in First-Line Treatment of Nonsquamous Advanced NSCLC

Mise à jour : Il y a 4 ans
Référence : EUCTR2008-006732-35

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective of this Phase 2 study is to assess the efficacy of pemetrexed-cisplatin combined with bevacizumab as induction therapy and pemetrexed-bevacizumab as maintenance therapy in the first-line treatment of patients with Stage IIIB or IV nonsquamous NSCLC, as measured by PFS.

Critère d'inclusion

  • Patients who have a histologically or cytologically documented diagnosis of nonsquamous stage IIIB or stage IV NSCLC that is not amenable to curative therapy

Liens